JP2023096009A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023096009A5 JP2023096009A5 JP2023080165A JP2023080165A JP2023096009A5 JP 2023096009 A5 JP2023096009 A5 JP 2023096009A5 JP 2023080165 A JP2023080165 A JP 2023080165A JP 2023080165 A JP2023080165 A JP 2023080165A JP 2023096009 A5 JP2023096009 A5 JP 2023096009A5
- Authority
- JP
- Japan
- Prior art keywords
- double
- stranded
- pharmaceutical composition
- sequence
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025034711A JP2025093992A (ja) | 2018-02-21 | 2025-03-05 | 変異P53特異的siRNAを使用した標的癌治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201801432S | 2018-02-21 | ||
| SG10201801432S | 2018-02-21 | ||
| JP2020544431A JP2021514195A (ja) | 2018-02-21 | 2019-02-21 | 変異P53特異的siRNAを使用した標的癌治療 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544431A Division JP2021514195A (ja) | 2018-02-21 | 2019-02-21 | 変異P53特異的siRNAを使用した標的癌治療 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025034711A Division JP2025093992A (ja) | 2018-02-21 | 2025-03-05 | 変異P53特異的siRNAを使用した標的癌治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023096009A JP2023096009A (ja) | 2023-07-06 |
| JP2023096009A5 true JP2023096009A5 (cg-RX-API-DMAC7.html) | 2024-03-22 |
| JP7648675B2 JP7648675B2 (ja) | 2025-03-18 |
Family
ID=67687981
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544431A Pending JP2021514195A (ja) | 2018-02-21 | 2019-02-21 | 変異P53特異的siRNAを使用した標的癌治療 |
| JP2023080165A Active JP7648675B2 (ja) | 2018-02-21 | 2023-05-15 | 変異P53特異的siRNAを使用した標的癌治療 |
| JP2025034711A Pending JP2025093992A (ja) | 2018-02-21 | 2025-03-05 | 変異P53特異的siRNAを使用した標的癌治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544431A Pending JP2021514195A (ja) | 2018-02-21 | 2019-02-21 | 変異P53特異的siRNAを使用した標的癌治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025034711A Pending JP2025093992A (ja) | 2018-02-21 | 2025-03-05 | 変異P53特異的siRNAを使用した標的癌治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12508277B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3755802A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2021514195A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102741498B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111727254B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3090220A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202007450XA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019164451A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3755802A4 (en) | 2018-02-21 | 2021-11-17 | Singapore Health Services Pte Ltd | THERAPEUTIC TARGETING OF CANCER USING SPECIFIC RNASI FOR P53 MUTANTS |
| WO2021127184A1 (en) * | 2019-12-17 | 2021-06-24 | The Johns Hopkins University | MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING |
| CN115820636B (zh) * | 2022-09-02 | 2024-06-11 | 华南农业大学 | 靶向TP53基因的sgRNA及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2832154B1 (fr) * | 2001-11-09 | 2007-03-16 | Centre Nat Rech Scient | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene |
| EP3755802A4 (en) | 2018-02-21 | 2021-11-17 | Singapore Health Services Pte Ltd | THERAPEUTIC TARGETING OF CANCER USING SPECIFIC RNASI FOR P53 MUTANTS |
-
2019
- 2019-02-21 EP EP19758146.5A patent/EP3755802A4/en active Pending
- 2019-02-21 SG SG11202007450XA patent/SG11202007450XA/en unknown
- 2019-02-21 KR KR1020207026511A patent/KR102741498B1/ko active Active
- 2019-02-21 CN CN201980013819.2A patent/CN111727254B/zh active Active
- 2019-02-21 US US16/971,626 patent/US12508277B2/en active Active
- 2019-02-21 WO PCT/SG2019/050099 patent/WO2019164451A1/en not_active Ceased
- 2019-02-21 JP JP2020544431A patent/JP2021514195A/ja active Pending
- 2019-02-21 CA CA3090220A patent/CA3090220A1/en active Pending
-
2023
- 2023-05-15 JP JP2023080165A patent/JP7648675B2/ja active Active
-
2025
- 2025-03-05 JP JP2025034711A patent/JP2025093992A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | The roles of ZEB1 in tumorigenic progression and epigenetic modifications | |
| Moradi‐Marjaneh et al. | Toll like receptor signaling pathway as a potential therapeutic target in colorectal cancer | |
| Deng et al. | Molecular mechanisms of anti-metastatic activity of curcumin | |
| Shi et al. | Application potential of toll-like receptors in cancer immunotherapy: Systematic review | |
| Jeon et al. | Combining microRNA-449a/b with a HDAC inhibitor has a synergistic effect on growth arrest in lung cancer | |
| Potenza et al. | MicroRNA‐125a‐5p is a downstream effector of sorafenib in its antiproliferative activity toward human hepatocellular carcinoma cells | |
| WO2025054270A1 (en) | Compositions and methods for treating cancer | |
| RU2017126601A (ru) | Способы и композиции для лечения злокачественных опухолей, ассоциированных с мутацией kras | |
| Zhang et al. | Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of leukemia cells via down-regulating P-gp | |
| Ramezankhani et al. | Novel molecular targets in gastric adenocarcinoma | |
| TWI855246B (zh) | 使用腫瘤治療電場(tt電場)之組合治療 | |
| Katsushima et al. | Long non-coding RNAs in brain tumors | |
| Boulware et al. | Triplex‐forming oligonucleotides targeting c‐Myc potentiate the anti‐tumor activity of gemcitabine in a mouse model of human cancer | |
| JP2018515130A5 (cg-RX-API-DMAC7.html) | ||
| Xiao et al. | Dig the root of cancer: targeting cancer stem cells therapy | |
| Saad et al. | Exosome-mediated crosstalk between cancer cells and tumor microenvironment | |
| JP2018512858A (ja) | 癌治療のためのヒト抗原R発現のsiRNA阻害 | |
| Krantz et al. | Pancreas adenocarcinoma: novel therapeutics | |
| Saatloo et al. | Akt1 and Jak1 siRNA based silencing effects on the proliferation and apoptosis in head and neck squamous cell carcinoma | |
| Liu et al. | Trichostatin A promotes esophageal squamous cell carcinoma cell migration and EMT through BRD4/ERK1/2‐dependent pathway | |
| Zhou et al. | Circular RNA-regulated autophagy is involved in cancer progression | |
| Peng et al. | Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line | |
| Nie et al. | The role of notch signaling pathway and non-coding RNAs in cancer and inflammation: Progress, therapeutic insights, and future directions | |
| Hou et al. | Research on curcumin mediating immunotherapy of colorectal cancer by regulating cancer associated fibroblasts | |
| JP2023126901A (ja) | 膵癌細胞の浸潤転移抑制剤 |